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The current world-wide economic recession has meant that the
decision-making process for purchasing new instrumentation
has gained more importance and priority for laboratory
managers.
The process requires careful consideration of cost and, even
more important, comparable data on the reliability and depend-
ability of a particular instrument. At the present time it is often
very difficult to obtain objective, comparable data. When a new
item ofequipment comes on the market a prospective purchaser
often has little information about its performance, other than
that from the manufacturer, or perhaps a colleague who might
have done a trial for the manufacturer. Neither of these sources
could be considered independent and it is unlikely that any
testing will have followed a carefully designed and internation-
ally accepted protocol. Therefore, many laboratories perform
extensive evaluation studies before a purchase decision is made.
Standardization of evaluation studies would improve the
comparability of the results reported Several national and
international organizations are involved in standardizing the
procedure for instrument testing, especially for evaluations of
analytical analysers. Some examples are listed in table 1. These
Table 1. Evaluation protocols proposed by various
organizations.
Proposed evaluation standards
Recommended scheme for the evaluation
of instruments for automatic analysis
in the clinical biochemistry laboratory
Protocol for establishing performance
claims for clinical chemical methods
Recommendations for multi-centre
evaluations of analytical instruments
Protocol for the evaluation of analytical
instruments
Protocol for the evaluation of automatic
blood-cell counters
Provisional guidelines for a short-term
assessment for inter-laboratory
acceptance of clinical laboratory
instrumentation
Organization
British Society for
Clinical Chemistry [1]
NCCLS [2]
German Society for
Clinical Chemistry [3]
ECCLS [4]
ICSH (not yet
published)
IIFCC (not yet
published)
protocols are all similar; therefore, they should be combined into
one internationally acceptable recommendation. However, it
appears that it is difficult to produce a single document to serve
everyone’s purposes. At least three evaluation stages have been
identified for an instrument new to the market. Each stage has its
own purpose, so a different protocol for each is required (these
are presently elaborated by various organizations).
The first stage (see table 2) is completely in the responsibility
ofthe manufacturer. The experiments can either be performed in
the factory or in external users’ laboratories. It is common for
manufacturers to ask one or several routine laboratories for an
evaluation with various goals:
(1) To detect weak points, since routine conditions are hard
to simulate in a company’s laboratory.
(2) To solve possible problems in sample- and data-
handling.
(3) To obtain an external publication which is considered a
useful advertisement.
(4) To establish performance criteria.
The American National Committee for Clinical Laboratory
Standards (NCCLS) has published several documents for this
purpose.
Evaluations organized by a manufacturer are usually re-
garded as an essential part of a responsible quality-control
programme for the production process. External evaluations are
presumably less cost-effective than internal studies with com-
parable expenditure. No time scale can be suggested for stage
because modifications of the instrument are often required.
Lists of specifications, which should be provided by the
manufacturer, have been worked out and published by the
International Federation of Clinical Chemistry’s (IFCC) Expert
Panel on Instrumentation (EPI) for analysers and several other
types of instrumentation (table 3). It is to be hoped that these
guidelines will soon be adopted by manufacturers and
customers.
Table 2. Stage 1 evaluation.
Primary 9oah establishment of performance criteria
Responsibility: manufacturer
Production line: prototype(s) of instruments for the
zero/first production line
Location: no recommendation
Time required: no recommendation
Document prepared by NCCLS
Table 3. Recommendations by the IFCC’s Expert Panel
on Instrumentationfor listing specifications by the
manufacturer.
Provisional guidelines for listing specifications
of spectrometers (see references I-8, 9 and 10])
of analysers [11]
of flame-emission spectrometers [12]
of atomic absorption spectrometers [13]
of nephrelometers (in preparation)
of blood-gas analysers (in preparation)
of ion-selective electrodes (in preparation)
The principal goal of stage 2 is to verify the specifications
which have been set up during stage (table 4). During a 1978
workshop conference organized by the Commission of the
European Communities under the title ’A plan for the use of
national resources for evaluating instruments employed in
clinical laboratory sciences’, the idea ofa co-ordinated multi-
centre evaluation trial was proposed as a way of achieving
comparability between the results from different laboratories.
Such multi-centre evaluations should last for no more than three
to six months.
88Table 4. Stage 2 evaluation.
Primary goal: verification of performance criteria
established during stage
Responsibility: some users in consultation with the
manufacturer
Production line: instruments from the first, or,
even better, from later production lines
Location: several users’ routine laboratories
Time required: three to six months
Document prepared by ECCLS/ICSH
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Table 5. Stage 3 evaluation.
Primary goal: checking of performance criteria
(established during stage and
verified in stage 2)
Responsibility: all users
Production line: from any production line
Location: user’s laboratory
Time required: about two weeks
Document prepared by EPI of IFCC
This concept has been adopted by a working group of the
German Society for Clinical Chemistry. The document publish-
ed by this group has been revised by the ad hoc Committee for
Instrument Testing [4] ofthe European Committee for Clinical
Laboratory Standards (ECCLS); the concept is summarized in
figure 1. Some specifications (safety and technical specifications
for example) are verified simply by an auditing of the manu-
facturer, others by performing experiments in clinical
laboratories.
Although special attention was paid to the statistical part of
the document, several comments received show that it is difficult
to find a proposal which suits all possible users. There seems to
be general agreement that classical regression analysis should be
abandoned in favour of either standardized principal com-
ponent analysis [-5] or another non-parametric procedure [6].
Further attention has been paid to the presentation and
reduction of the numerous data obtained during a multi-centre
evaluation.
exam nation p racticab ity
Preparation of individual protocol
following the recommendation laid down
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with the manufacturer
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Figure 1. Multi-centre concept for the evaluation of
analysers according to a draft proposal ofECCLS.
In stage 1, performance claims can be obtained by following
the NCCLS protocols especially designed for this purpose. It
may also be possible to use parts of the multi-centre protocol to
determine precision, accuracy, carry-over, etc., in either the
manufacturer’s own and/or external laboratories. The labora-
tories establishing and verifying the claims should not be
identical, some overlap, however, may be acceptable. Data
obtained from a multi-centre evaluationmay later be used by the
manufacturer when performance characteristics are published.
The third and last stage (.table 5) is intended for all
instruments made on a production line. This evaluation should
be performed by all laboratories before a new instrument is used
for the analysis of samples from patients, to check whether the
performance criteria established and verified in stages and 2
still hold. Evaluation studies in stage 3 require only about two
weeks.
The three-stage concept was first suggested by the European
groups I-4 and 7] but it is also proposed in a draft document
recently distributed by the International Committee for
Standardization in Haematology (ICSH). This document has
many features in common with the ECCLS draft standard:
(a) Multi-centre trials.
(b) Definition oftolerance limits: prior to the evaluation the
acceptable limits of precision and accuracy should be
stated. These will depend on the manufacturer’s claims
and on clinical requirements.
(c) Familiarization period.
(d) Safety assessment.
Other proposals in the ICSH document which are not covered
by the ECCLS standard are:
(i) Participation in national external quality-assessment
schemes.
(ii) Details for calibration procedures on quality control
materials and for sample collection.
Differences exist in terminology concerning imprecision and in
statistical procedures.
The concept of three stages more or less reflects the present
procedure adopted by larger companies introducing a newly
developed analyser. Although this procedure is already followed
in many cases, it is important that the concept is generally
accepted before standardization proceeds further. Since volun-
tary trials are proposed, the concept is not considered as a
pre-market approval procedure.
It is proposed that only a few laboratories should conduct
standardized and co-ordinated multi-centre evaluations; their
results would then be used by most laboratories for selecting new
instrumentation. For a final decision only a short testing period
of two weeks is required.
Experiences with the present situation have shown that
single-centre evaluations are not always accepted, especially
outside the country in which they were performed; and that
instrument companies seldom use only one laboratory for their
evaluation studies. This situation can be called ’multiple one-
centre evaluations’. The disadvantages are that the time
involved before reports from several sites are published is
considered to be over long; the data produced on the various
laboratories are often not comparable because differences exist
in experimental design; the number of evaluations required by
European users is usually considered to be too high by the
manufacturers; and there is much wastage ofpersonnel and
scientific resources.
Therefore, the next step would be to co-ordinate several
trials in one multi-centre evaluation. Major advantages of this
concept are:
(1) Comparable data on the reliability of new instruments
from several laboratories would be produced.
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(2) Information about new instruments would be more
easily accessible.
(3) The data would be more objective because the results
would be more independent of the manufacturer. The
degree of objectivity obtained by a multi-centre study
cannot be reached by single laboratories.
(4) Unnecessary replication ofnumerous evaluations would
be avoided.
(5) Expert and financial resources would be used optimally.
(6) Instrument improvement would be stimulated.
Advantages (1), (2) and (3) improve the basis for decision-making
on purchases; (4) and (5) mean that less manpower and cost
would be required from the manufacturer. Advantage (6) creates
improved feedback of laboratory experience to the manu-
facturer. The data are much more meaningful if they are
obtained in several laboratories under comparable conditions.
Assuming that the three-stage concept is accepted, the next
step should be harmonization of the various protocols already
elaborated concerning terminology and basic features to be
tested.
This harmonization has already been achieved between the
present version of the stage 2 document published by ECCLS
and the stage 3 document elaborated by the IFCC’s EPI. No
attempts have been made to harmonize these documents with
the stage documents worked out by NCCLS. This has led to
some misunderstandings. The NCCLS documents have been
used for stage 2 purposes; similarly, the ECCLS stage 2 protocol
could be used as a guideline for stage 1.
Experiences with the present ECCLS protocol have shown
that several specific documents are required for each class of
instrument, for instance for spectrometers, chemical analysers,
blood-gas analysers and so on.
In conclusion, the three-stage concept for testing new
instrumentation should generally be accepted and the perform-
ance of multi-centre evaluations should be endorsed on a
voluntary basis.
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AUTOMATIC CHEMICAL ANALYSIS
The 6th Summer School of Automatic Chemical
Analysis was held at the University of Sussex,
Falmer, Brighton, UK from to 6 July 1984. Key
topics were automation, computing, and laboratory
management. The Summer School is intended to
enable analysts from a wide range of industries to
acquire the basic skills needed for laboratory autom-
ation; experienced users of automated systems should
have their knowledge and appreciation of the latest
developments in the field improved.
Each year the organizers of the School evaluate
participants’ comments and consider ways of improv-
ing the course. Consequently, the 6th School em-
phasized automated chemistry and contained less on
computing. The proven format of an integrated series
of lectures, tutorials and practical sessions was
retained.
The emphasis on automated chemistry was re-
flected in both the lecture topics and the list oflecturers
and tutors; new names included Professor Ray Dessy
from Virginia State Polytechnic, USA, and Professor
Jarda Ruzicka from the Technical University of
Denmark.
Information about the 1985 School from Beverly
Humphrey, Summer School of Automatic Chemical
Analysis, 176a North View Road, London N8 7NB, UK.
NEW JOURNAL
Food Additives and Contaminants
Taylor & Francis Ltd, publisher of Journal of
Automatic Chemistry, launched a new quarterly called
Food Additives and Contaminants at the beginning of
the year.
The journal contains original contributions and
review articles relating to the detection, determination,
occurrence, persistence, safety evaluation and control
of naturally occurring and man-made additives and
contaminants in the food chain.
Subjects covered include:
Naturally occurring toxins
Residues of environmental contaminants, in-
cluding pesticides
Substances added during food and beverage
processing
Contaminants arising from packaging and
storage
Naturally occurring--or added--vitamins, hor-
mones, antibiotic or drug residues
The effects resulting from enzymic or radiation
processes
Surveillance and indentification of groups at
risk
Implications ofnational and international legis-
lation on food quality
Chemical form and other factors affecting
bioavailability.
The editors are Drs R. Walker and M. E. Knowles.
Enquiries (1984 prices are 37.00, $74.00 and
DM 167.00) to Taylor & Francis Ltd, Rankine Road,
Basin.qstoke, Hampshire RG24 OPR, UK.